

March 2015

No Images? [Click here](#)

Welcome to our Quarter 1 newsletter for 2015 which aims to provide customers with an insight into our activities, service updates and research and development. Please visit our new website www.resonancehealth.com - we would love to hear your comments at info@resonancehealth.com

Customer Focus: UCL Heart Hospital Project

Resonance Health was delighted to be invited to work with Professor James Moon (UCL Heart Hospital, UK) and his London research group to design and manufacture MRI phantoms for use in a quantitative cardiac T1 imaging standardisation programme. Cardiac T1 mapping has applications in cardiac disease monitoring, including myocarditis, myocardial oedema, fibrosis, amyloidosis and siderosis.

Approximately 60 phantoms (comprising 12 test-tube solutions which form a set of 'standards') will be manufactured and distributed to leading cardiac magnetic resonance centres throughout the world. A central lab at UCLH, London will use the extensive data generated by the phantom scanning over the next 12 months to instigate T1 mapping standardisation.

Andrew Bathgate, Quality Assurance and Regulatory Affairs Manager at Resonance Health said:



Liver Forum and EASL, Vienna April 2015

Resonance Health will be attending the 2nd Liver Forum in Vienna in April as a prelude to the European Association of the Study of the Liver (EASL) conference which sees around 10,000 delegates attend each year. The forum provides an arena for the FDA clinical fraternity, pharmaceutical and invited organisations to hold open discussions on clinical development

We welcome the opportunity to bring our core lab capabilities and expertise in clinical studies to this exciting Cardiac T1 mapping project as part of their standardisation programme. This project enables us to collaborate with world leading Cardiac Centres and MRI manufacturers and to potentially provide phantoms as well as cardiac T1 mapping services in future cardiac disease related multicentre clinical studies.



SCMR/ISRM Conference Nice, France. Left to Right: Andrew Bathgate, QA/RA Manager (Resonance Health) Dr Gabriella Captur (UCL) holding demonstration phantom, Prof James Moon, (UCLH), Friso Heslinga (UWA Masters Student)



MRI Measurement of Liver Iron Concentration

Global Access to the Gold-Standard MRI for Liver Iron Concentration

and drug trials to advance health outcomes in liver disease.

Chief Scientific Officer at Resonance Health, Prof. Tim St Pierre said:

We look forward to contributing to the Liver Forum and will also present the latest data on HepaFat-Scan® to the clinical community at the EASL conference.

Please come and visit our team at exhibition stand # 440 I where we will be delighted to meet you.



Role of HepaFat-Scan in Liver Cancer Surgery

Commencing this quarter, the application of HepaFat-Scan in liver cancer surgery will be investigated. This Australian based, multi-centre, randomised

Resonance Health continues to strengthen collaborations with stakeholders from the clinical and patient communities and is currently undertaking joint activities with the Pan-European imaging chain, Alliance Medical Ltd in the UK to provide better access to FerriScan throughout the country.

As part of an ongoing clinical education programme FerriScan has also been profiled at key clinical meetings in Europe, including the Thalassaemia International Federation (TIF) Conference in Athens to over 500 delegates. The updated TIF guidelines are now available which reference FerriScan (R2-MRI) for monitoring of Liver Iron Concentration <http://www.thalassaemia.org.cy>.

A recent abstract presented at the American Society of Haematology (ASH) by an Italian network of hospitals also advocated the crucial role FerriScan plays in management of Haemoglobinopathy patients.

<https://ash.confex.com/ash/2014/webprogram/Paper70043.html>

This year, the company will continue to focus on improving access to FerriScan in countries where there are large numbers of patients and limited access to accurate quantitative MRI measurement of Liver Iron Concentration. In the last six months FerriScan has become available in many new countries including most recently Bulgaria and Romania.

New Website and Logos For Resonance Health

Resonance Health has completed work on the redevelopment of our existing website and have updated our logos. The web pages have a fresh new look with contemporary design guidelines including responsive design, allowing easy access via portable devices such as tablets and

clinical study will involve comparing the clinical outcomes of patients with colorectal metastases who receive HepaFat-Scan before surgery with those who do not receive HepaFat-Scan. The study follow up period will be 6 months post surgery. The study aims to help liver surgeons optimise their surgical plan, resulting in better clinical outcomes for the patient(s). Preliminary results are expected late 2016.

Team Member In Focus: Sander Bangma General Manager

Sander Bangma joined Resonance Health in 2005 and has recently been appointed General Manager. Born and raised in the Netherlands, he completed his studies at Utrecht University before moving to Australia. He holds a Master's Degree in Computer Science and completed a Diploma in

mobile phones. The new website offers improved speed and reliability together with up-to-date features and general user friendliness. We look forward to comments and feedback on the new site from our valued customers.

Please visit us at www.resonancehealth.com



China Delegation

In January, key members from the R&D and Marketing teams undertook a trip to China to continue the commercialisation of both HepaFat-Scan and FerriScan in the China market. The team met with Key Opinion Leader's in hospitals around Beijing, Shanghai, Nanjing and Guangzhou.


Wenjie Pang, Technical and Research Manager said:

The use of FerriScan and awareness of the value to the clinical community continues to grow in China and the visit has been fruitful with strong interest in HepaFat-Scan and anticipated trialing to commence within the year.

Management.

Throughout his time with Resonance Health he has gained a wealth of experience in the day-to-day operations of the Company. Sander previously held a dual role in the Company as Development Manager and Service Centre Manager. In these roles his responsibilities included overseeing all software medical device development activities, IT infrastructure and the Company's Intellectual Property portfolio, as well as all facets of Resonance Health's analysis service provision. He continues to hold overall responsibility for these areas. In his spare time he enjoys going for a bike ride along Perth's beautiful Swan River and taking the kids to the beach.





Wenjie Pang and Prof. Yan

Coming Soon

- A clinical study in a leading USA hospital is planned to substantiate the role of HepaFat-Scan in Non Alcoholic Fatty Liver Disease.
- Thalassaemia Meeting May 8th in Palermo will showcase the FerriScan R2-Network 'LICNET' led by Prof. Maggio with Prof. Tim St Pierre an invited speaker.
- Continued work on our Fibrosis technology, R&D update next issue.

Resonance Health
278 Stirling Highway Claremont WA 6010 Australia
www.resonancehealth.com



TWEET



FORWARD

You are receiving this email as you are registered in FAST or have expressed interest in Resonance Health and/or our services

Preferences | Unsubscribe

□